Peijia Medical Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Peijia Medical yıllık ortalama 38.7% oranında kazançlarını artırırken, Medical Equipment sektöründe kazançlar declining at 1.1% annual. Gelirler yılda ortalama 53% oranında büyüyor .

Anahtar bilgiler

38.7%

Kazanç büyüme oranı

62.2%

EPS büyüme oranı

Medical Equipment Sektör Büyümesi	4.3%
Gelir büyüme oranı	53.0%
Özkaynak getirisi	-11.5%
Net Marj	-48.6%
Son Kazanç Güncellemesi	30 Jun 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Gelir ve Gider Dağılımı

Peijia Medical nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

DB:4WO Gelir, gider ve kazançlar (CNY Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
30 Jun 24	517	-252	446	223
31 Mar 24	479	-322	456	214
31 Dec 23	441	-393	467	205
30 Sep 23	399	-460	457	182
30 Jun 23	357	-528	447	159
31 Mar 23	304	-468	406	153
31 Dec 22	251	-408	365	147
30 Sep 22	227	-449	325	149
30 Jun 22	204	-491	285	151
31 Mar 22	170	-533	246	141
31 Dec 21	137	-574	208	131
30 Sep 21	106	-515	176	123
30 Jun 21	76	-455	143	114
31 Mar 21	57	-1,262	141	109
31 Dec 20	39	-2,069	139	103
30 Sep 20	33	-2,128	180	92
30 Jun 20	28	-2,187	221	80
31 Mar 20	23	-1,360	201	68
31 Dec 19	19	-532	181	55

Kaliteli Kazançlar: 4WO şu anda kârlı değil.

Büyüyen Kar Marjı: 4WO şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: 4WO kârlı değildir, ancak son 5 yılda zararlarını yılda 38.7% oranında azaltmıştır.

Büyüme Hızlandırma: 4WO 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: 4WO kârlı olmadığından, geçmiş yıl kazanç büyümesinin Medical Equipment sektörüyle ( 10.1% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: 4WO hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -11.54% ) sahiptir.

Peijia Medical Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

First half 2024 earnings released: CN¥0.10 loss per share (vs CN¥0.31 loss in 1H 2023)

Peijia Medical Limited to Report First Half, 2024 Results on Aug 23, 2024

Peijia Medical Limited to Report Fiscal Year 2023 Results on Jun 15, 2024

Peijia Medical Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

First half 2023 earnings released: CN¥0.31 loss per share (vs CN¥0.14 loss in 1H 2022)

First half 2023 earnings released: CN¥0.31 loss per share (vs CN¥0.14 loss in 1H 2022)

Recent updates

Peijia Medical Limited Announces Resignation of Yu Zhiyun as Non-Executive Director and A Member of the Board's Remuneration Committee

First half 2024 earnings released: CN¥0.10 loss per share (vs CN¥0.31 loss in 1H 2023)

Less than half of directors are independent

Peijia Medical Limited, Annual General Meeting, Sep 30, 2024

Peijia Medical Limited to Report First Half, 2024 Results on Aug 23, 2024

Peijia Medical Limited to Report Fiscal Year 2023 Results on Jun 15, 2024

Peijia Medical Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

Peijia Medical Announces Successful Completion of Patient Enrollment for Pivotal TaurusTrio Transcatheter Aortic Regurgitation Clinical Trial

First half 2023 earnings released: CN¥0.31 loss per share (vs CN¥0.14 loss in 1H 2022)

Less than half of directors are independent

Forecast to breakeven in 2025

First half 2023 earnings released: CN¥0.31 loss per share (vs CN¥0.14 loss in 1H 2022)

New major risk - Share price stability

Peijia Medical Limited to Report First Half, 2023 Results on Aug 31, 2023

Peijia Medical Limited Announces First Patient in Multi-Center Registration Clinical Trial of Taurustrio™? Transcatheter Aortic Valve Replacement System in China

Peijia Medical Limited Provides Unaudited Revenue Guidance for the Period from January 1, 2023 to June 30, 2023

New minor risk - Profitability

Peijia Medical Limited Receives Approval from the National Medical Products Administration of the PRC for the Registration Application of DCwireTM Micro Guidewire

New minor risk - Share price stability

Executive Director & Company Secretary recently sold €362k worth of stock

Forecast to breakeven in 2025

Peijia Medical Limited Announces First Patient Enrollment in the Multi-Center Registration Clinical Trial of Geminione Transcatheter Edge-To-Edge Repair System in China

Peijia Medical Limited Announces in Partnership with inQB8 Medical Technologies, LLC Successfully Completed the First Patient Implant in the First-In-Man Clinical Trial of the MonarQ Transcatheter Tricuspid Valve Replacement System in the World

Less than half of directors are independent

Peijia Medical Limited Announces First Patient Implant in Multi-Center Registrationclinical Trial of Peijia Highlife Transcatheter Mitralvalve Replacement System in China

Less than half of directors are independent

First half 2022 earnings released: CN¥0.14 loss per share (vs CN¥0.27 loss in 1H 2021)

Peijia Medical Limited to Report First Half, 2022 Results on Aug 19, 2022

Forecast to breakeven in 2024

Peijia Medical Limited Announces Executive Changes

Peijia Medical Limited Receives NMPA Approval for Registration Application of Fluxcap Balloon Guide Catheter

Peijia Medical Limited Receives the Approval from the National Medical Products Administration of the PRC for the Registration Application of Tethys AS Aspiration Catheter

Peijia Medical Limited, Annual General Meeting, Jun 10, 2022

Full year 2021 earnings released: CN¥0.87 loss per share (vs CN¥4.43 loss in FY 2020)

Less than half of directors are independent

Full year 2021 earnings released: CN¥0.86 loss per share (vs CN¥4.43 loss in FY 2020)

Peijia Medical Limited to Report Fiscal Year 2021 Results on Mar 31, 2022

Peijia Medical Limited Receives the Approval from the National Medical Products Administration for Syphonet® Stent Retriever

Peijia Medical Limited Announces First Patient Implant in Research Clinical Trial of Peijia's Highlife Trans-Septal Mitral Valve Replacement System in China

Peijia Medical Announces First Patient Implant in the Clinical Trial of Its Third-Generation Transcatheter Aortic Valve System TaurusNXT

Peijia Medical Limited Announces First Patient Implant in Clinical Trial of TaurusNXT

First half 2021 earnings released: CN¥0.27 loss per share (vs CN¥8.68 loss in 1H 2020)

Peijia Medical Limited Receives the Approval from the National Medical Products Administration of the PRC of the Registration Application for TaurusElite

Full year 2020 earnings released: CN¥4.43 loss per share (vs CN¥2.33 loss in FY 2019)

Full year 2020 earnings released: CN¥4.43 loss per share (vs CN¥2.26 loss in FY 2019)

Peijia Medical Limited to Report Fiscal Year 2020 Results on Mar 29, 2021

Peijia Medical Limited Announces Patient Enrollment for the Clinical Trial Ofshenyi Stent Retriever

New 90-day high: €3.20

New 90-day low: €2.34

New 90-day low: €2.60

Peijia Medical Limited Announces Completion of Patient Enrollment for the Clinical Trial of Tauruselite

Peijia Medical Limited to Report First Half, 2020 Results on Aug 28, 2020

Gelir ve Gider Dağılımı

Kazanç ve Gelir Geçmişi

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Özkaynak Getirisi

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin